Wed, 05 Feb 2025

Wed, 05 Feb 2025 Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

* Novo Nordisk's obesity drug Wegovy has lost market share to rival Zepbound from Eli Lilly, according to prescription data from IQVIA.
* The company's stock has fallen over 20% in the last year, but recent earnings and sales guidance have boosted its value by more than 4%.
* CEO Lars Fruergaard Jorgensen says Novo is confident it can regain market share as it supplies more starter doses of Wegovy and Ozempic.
* The company's 2025 sales guidance implies a 30% increase in patients taking GLP-1 drugs, including Ozempic.
* Novo has reassured investors about the effectiveness of its new drug CagriSema, despite disappointing trial results.
* Another experimental treatment, amycretin, has shown promising results and may move straight to phase three trials.
  >>